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Serum anti-(GalNAcβ) and anti-para-Forssman disaccharide (PFdi, GalNAcβ1–3GalNAcβ) IgG levels were earlier found to be re-
lated to histological grading and progression of gastrointestinal cancer. Aim: To study the relation of serum antibodies level to sur-
vival in patients with gastrointestinal cancer. Methods: The level of anti-GalNAcβ, and PFdi IgG was analysed in the serum of patients 
with gastric (n = 78) and colorectal (n = 48) cancers in the long-term follow-up using ELISA with polyacrylamide glycoconjugates. 
Survival rate and hazard ratio (HR) were assessed by the Kaplan — Meier method and Cox univariate analysis in different patho-
morphological groups. Results: Better survival was observed in patients with an increased preoperative level of GalNAcβ antibodies. 
These were the gastrointestinal group in stages II, III or tumors T2–4 (n = 90–104, P = 0.007, HR = 0.48–0.49, 95% CI 0.27–0.83, 
and the group with gastric cancer in stages I, II (n = 49, P = 0.051, HR = 0.39, 95% CI 0.14–1.04). The survival time was signifi-
cantly longer in the gastrointestinal group in patients whose GalNAcβ antibodies level rose in dynamics (stage III or N1–2: P = 
0.031–0.039, HR = 0.29–0.31, 95% CI 0.09–1.00). No significant difference in survival of patients was observed in the evaluation 
of PFdi antibodies. We suggest that the level of antibodies and its change reflect the enteric microbiota colonization, which may influ-
ence cancer progression via different interrelations between microbiota, the tumor and immune system. Conclusion: The preoperative 
level of GalNAcβ antibodies and its dynamics may be of prognostic significance for clinical outcome assessment.
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Enteric microbiota that colonize the alimentary tract 
stim�late the prod�ction of carbohydrate antibodies 
in h�mans. The individ�al pattern and level of carbohy­
drate antibodies in the ser�m of patients with gastroin­
testinal cancer may be changed beca�se of the altered 
colonization� bacterial translocation and inflammatory 
response [�� �]. The antibody level may reflect the adap­
tive imm�ne response of the host to enteric microorga­
nisms in carcinogenesis that deserves a circ�mstantial 
investigation for cancer diagnostics and prognosis. 
Comparative data abo�t spontaneo�sly occ�rring 
carbohydrate antibodies in cancer� their a�toreactivity 
to the glycans of the host incl�ding t�mor­associated 
carbohydrate antigens� dynamic changes and relation 
to s�rvival are scanty. The PAA­glycoconj�gates that are 
homogeno�s antigens with a single reiterative glycotope 
[�] were �sed for the determination of carbohydrate 
antibodies. Owing to the high reprod�cibility and low 
backgro�nd in ELISA� significant differences in the 
level of antibodies were demonstrated in comparative 
investigations [4��]. We have �ndertaken a long­term 
follow­�p st�dy to clarify the relation of the ser�m level 
of carbohydrate antibodies to s�rvival and its prognostic 
significance. Patients with elevated levels of IgG anti­
bodies to conj�gates of Thomsen­Friedenreich disac­
charide �TF� Galβ���GalNAc� and Tn �GalNAcα) showed 
a longer s�rvival time while the s�rvival time was shorter 
in patients with an elevated level of aGal �Galβ���Galβ� 
antibodies. In different patho­morphological gro�ps� 
the preoperative levels of antibodies and their dynamics 
were fo�nd to be of prognostic val�e �the man�script 
is presented for p�blication�.
We tested the ser�m of patients by ELISA� �sing 
a set of PAA­β­glycoconj�gates� and fo�nd pop�la­
tions of IgG antibodies to be reactive to GalNAcβ and 
GalNAcβ���GalNAcβ �PFdi� ligands [�]. The anti­PFdi 
IgG ser�m level was significantly higher in patients with 
gastric and colorectal cancer than in donors. Moreower� 
the elevated anti­PFdi IgG level was associated with the 
advanced gastric cancer [6].
The aim of the present st�dy was to eval�ate whether 
the level of GalNAcβ and PFdi IgG antibodies and the 
respective changes are related to s�rvival� taking also 
into consideration the stage of the disease� t�mor size 
stat�s� morphology and the t�mor spread in regional 
lymph nodes.
MATERIALS AND METHODS
Patients. The investigation was carried o�t in ac­
cordance with the ICH GCP Standards and approved 
by Tallinn Medical Research Ethics Committee� Estonia. 
The informed consent was obtained from each patient 
�nder examination. Altogether sixty­fo�r male and sixty­
two female patients� among them seventy­eight with 
gastric and forty­eight with colorectal cancer in stages 
I�III� were s�bjected to a long­term follow­�p. Diagnosis 
was verified by the pTNM system [��]. Patients with 
distant metastases or those who received chemo­ and 
X­ray therapy� as well as individ�als who d�ring dynamic 
investigations s�rvived less than three months after 
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s�rgery were excl�ded from the st�dy. The median age 
of patients was 64 years� mean ± SD: 6�.6 ± �.7. The 
extended D� gastrectomy with limphadenectomy and 
resection of local lesions for colorectal cancer were 
performed. Regional lymph node metastases were also 
removed in advanced cancer. Concomitant diseases 
were doc�mented in some patients. Inflammatory 
diseases �enterocolitis� pancreatitis and cholecystitis� 
and postoperative complications were revealed in �7% 
of patients� anaemia in five cases� and diabetes mel­
lit�s in three cases. The other sporadic manifestations 
were breast cancer� the carcinoma of the �ter�s� Par­
kinson’s disease� cystitis� pyelonephritis and chronic 
hepatitis. Veno�s blood samples were taken before 
and after a s�rgical operation� and d�ring the planned 
visits to the physician for health control. Ser�m probes 
were stored at ��� °C before �se. The patients were 
divided into gro�ps by stages� t�mor vol�me T� and 
T��4� t�mor grade G��� and G�� and regional lymph 
node metastases N� and N���.
Glycoconjugates. The glycoconj�gates 
of poly[N­��­hydroxyethyl�acrylamide]� namely 
GalNAcβ­PAA and GalNAcβ���GalNAcβ­PAA �PFdi­
PAA�� were received from Lectinity� R�ssia. The epitope 
density was �� mol.%. Tris�hydroxymethyl�aminome­
thane­PAA �Tris­PAA� was �sed as a negative control.
The indirect ELISA. The assay was performed 
as described earlier [��]. The level of ser�m IgG an­
tibodies reactive to glycoconj�gates was estimated 
as the ratio of Atest/Acontrol� where Atest is the absorbance 
with glycoconj�gate and Acontrol� is the absorbance with 
Tris­PAA.
Statistical analysis. The level of antibodies and its 
dynamics were st�died in relation to overall s�rvival time 
starting from the date of the preoperatively taken blood 
sample. The Kaplan — Meier method and Cox �nivariate 
proportional hazards analysis were �sed �SPSS� ver­
sion ��.��. The median �M� of the level of GalNAcβ and 
PFdi antibodies �Table �� was �sed as a c�t­off to dis­
criminate between responders �R� whose antibody level 
was above or eq�al to M� and weak responders �WR� 
the level below M�. The difference in s�rvival between 
patient gro�ps was considered to be significant when 
p ≤ �.��. The linear regression analysis was performed 
�sing Statgraphics Pl�s �.�. The dynamic data were ap­
proximated to a q�adratic f�nction� �sing a C�rveFinder 
for C�rveExpert �Version �.�4�.
Table 1. Median and mean of the preoperative antibody level
Antibodies Group n Median Mean SD
GalNAcβ Gastrointestinal 126 1.34 1.70 1.02
PFdi 118 1.59 2.91 3.27
GalNAcβ Gastric 78 1.31 1.55 0.72
PFdi 75 1.53 2.90 3.28
GalNAcβ Colorectal 48 1.39 1.93 1.34
PFdi 43 1.69 2.94 3.30
RESULTS
The relation of the preoperative antibody level 
to survival. In different patho­morphological gro�ps 
with gastrointestinal or gastric cancer� GalNAcβ­
responders �GNA­R� demonstrated a significantly 
better s�rvival or a tendency to better s�rvival than 
GNA­WR while PFdi­R vers�s PFdi­WR revealed a weak 
tendency to worse s�rvival only. In gastrointestinal can­
cer� the significantly better s�rvival in GNA­R vs GNA­
WR was observed in stages II� III and t�mor vol�me 
T��4. In gastric cancer� a significantly better s�rvival 
in GNA­R was observed in stages II and II� III� N� gro�p 
�Table �� Fig�re�.
Table 2. The relation of the preoperative GalNAcβ antibody level in the se-
rum of cancer patients to survival
Group n p HR 95% CI Mean survival time, months*
Gastrointestinal, all 126 0.074 0.62 0.37–1.05 129.0; 108.6
Stages II, III 90 0.007 0.48 0.27–0.82 112.4; 80.3
T2–4 104 0.007 0.49 0.29–0.83
Gastric, Stages I, II 49 0.051 0.39 0.14–1.04 150.4; 113.9
Stage II 24 0.004 0.24 0.08–0.68 120.3; 54.2
Stages II, III, N0 22 0.010 0.26 0.09–0.77 118.2; 54.7
Note: *Responders vs weak responders.
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Figure. Probability of s�rvival in GNA­responders �the level 
of ser�m GalNAcβ antibodies above or eq�al to median M� a solid 
line� vs GNA­weak responders �the level below M� a dotted line�. 
a� b — the relation of the preoperative antibody level to s�rvival; 
c — the relation of the antibody level dynamics to s�rvival eval�­
ated by factor b. a — patients with T��4 t�mors of gastrointes­
tinal cancer. b — stages I�II of gastric cancer. c — patients with 
an N��� stat�s of gastrointestinal cancer
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No significant differences in s�rvival between 
GNA­R and GNA­WR� as well as between PFdi­R and 
PFdi­WR in coloractal cancer were observed. However� 
to verify this� more patients need to be investigated. 
We did not observe the relation of s�rvival to t�mor 
morphology in patients with gastric� colorectal or gas­
trointestinal cancer �G��� vs G�� p = �.�4��.�4�. 
S�rvival was not associated with the age of patients 
either �p = �.����. S�rvival was better in an N� sta­
t�s �N� vs N���� p = �.�46� n = ��4� HR = �.6�� ��% 
CI �.����.76�.
The relation of the antibody level dynamics 
to survival. The level of IgG antibodies to glycoconj�­
gates in the ser�m of patients changed after s�rgery 
[6� �]. We delineated the change of antibody level 
as a q�adratic f�nction Y = a + bX + cX2� where Y is the 
level of antibodies� X is the time in months� coefficient 
a is the factor characterizing the initial level of antibo­
dies� b and c are the factors characterizing the change 
of the antibody level. This f�nction showed a good fit 
to the data points �r = �.����.�6� and was applied to the 
calc�lation of factors for each patient. We did not exa­
mine the dependence of s�rvival on factor c beca�se 
of its insignificant infl�ence on antibody level dynamics. 
The medians of factors a and b �not shown� were �sed 
as c�t­off to discriminate between responders �the 
val�e above or eq�al to M� and weak responders �the 
val�e below M�.
Similarly to the res�lts of the preoperative assess­
ment� the s�rvival of GNA­R vs GNA­WR eval�ated 
by factor a was significantly better in patients of the 
gastrointestinal gro�p having T��4 t�mors. Eval�ated 
by factor b� the s�rvival of GNA­R vs GNA­WR was fo�nd 
to be significantly better in stage III or N��� of gastroin­
testinal cancer �Table ��. The PFdi­R vs WR in G��� t�­
mors of gastrointestinal cancer showed a tendency 
to differ in s�rvival as eval�ated by factor a or b.
Table 3. The relation of the antibody level dynamics to survival
Anti-
bodies
Gastro-
intestinal 
group
Fac-
tor n p HR 95% CI
Mean sur-
vival time, 
months*
GalNAcβ all a 79 0.076 0.48 0.21–1.10 161.1; 137.2
T2–4 a 67 0.026 0.39 0.16–0.92
Stage III b 28 0.031 0.29 0.09–0.96 150.1; 90.0
N1–2 b 32 0.039 0.31 0.09–1.00 151.6; 104.8
PF G1–2 a 40 0.073 3.86 0.80–18.68 134.0; 170.1
G1–2 b 40 0.079 0.27 0.06–1.29 169.2; 142.2
Note: *Responders vs weak responders.
DISCUSSION
This st�dy demonstrates that the s�rvival rate 
of patients with gastrointestinal cancer in some patho­
morphological gro�ps is associated with the ser�m 
level of GalNAcβ antibodies. To analyze the relation 
of antibodies level dynamics to s�rvival� we �sed fac­
tors calc�lated as coefficients of a q�adratic f�nction. 
A significantly longer s�rvival was observed in patients 
having T��4 t�mors and whose preoperative or initial 
level of GalNAcβ antibodies eval�ated by factor a was 
increased �Tables � and �� Fig�re�. A tendency close 
to the significant difference in s�rvival between patients 
was observed in the whole gastrointestinal gro�p and 
in stages I� II of gastric cancer. Noteworthy� a significant 
difference in GNA­R vs GNA­WR was observed in stages 
II� III or II� i.e., in gro�ps apart from stage I �Table ��.
The lower anti­GalNAcβ IgG level has been associ­
ated with lower­differentiated carcinomas. Besides� the 
elevation of GalNAcβ and PFdi antibodies level in patients 
with gastrointestinal cancer was revealed after a s�rgi­
cal removal of G�­t�mors [6]. However� this positive 
dynamics was not associated with s�rvival in G� gro�p. 
The elevation of GalNAcβ antibodies assessed by fac­
tor b was associated with a benefit in the s�rvival rate 
of patients with advanced cancer �stage III or N����.
We demonstrated earlier a significantly higher pre­
operative level of PFdi antibodies in patients with gastric 
and colorectal cancers than in donors. The elevated 
antibodies level was associated with the advanced 
gastric cancer: in stages II� III� IV vs stage I and in case 
of the t�mor size T�+T� vs T�. No relation between the 
antibodies level and regional and distant metastases 
of gastric or colorectal cancer was fo�nd [6]. However� 
eval�ated by the preoperative level of PFdi antibodies 
or that eval�ated by factors a and b, no significant 
difference in s�rvival rate between patient gro�ps was 
established in the present st�dy.
In patients with gastrointestinal cancer� the anti­
GalNAcβ IgG level has been correlated with the 
percentage of peripheral blood monocytes [6]. The 
GalNAcα/β resid�es are excl�sive ligands of the C­type 
lectin of h�man macrophages� which is involved in the 
�ptake and presentation of glycosylated antigens [��� 
��]. The GalNAcβ­related determinants are present 
in glycans of the bacterial cell wall. A host­like motif 
GalNAcβ���Gal is present in coaggregation receptor 
polysaccharides of different streptococcal strains [�4]. 
Enteric bacteria in h�man are more probable imm�no­
gens for antibodies with corresponding specificities. 
We eval�ated the specificity of IgG antibodies in ser�m 
probes of patients with gastrointestinal cancer� �sing 
PAA­glycoconj�gates in the competitive ELISA. IgG 
demonstrated the moderate cross­reactivity to GalNAcβ 
and related ligands� namely GalNAcβ���Galβ �X�di� 
the terminal disaccharide of the X� glycolipid� P­like 
antigen�� PFdi and GlcNAcβ. From low to moderate 
cross­reactivity of IgG antibodies to the pair GalNAcβ 
and Tn �GalNAcα� was observed in ser�m probes [�]. 
The IgG antibodies affinity­isolated on GalNAcβ­PAA­
Sepharose bo�nd mainly GalNAcβ and X�di� b�t bo�nd 
other related ligands weakly or not at all. The anti­X�di 
or anti­PFdi IgG antibodies isolated on affinity sorbents 
were specific to the corresponding ligand �sed in isola­
tion �man�script in preparation�.
The X� and sialosyl­X� glycolipids are present 
in h�man erythrocytes as well as normal and t�mor 
tiss�es as extreme minor components� b�t are fo�nd 
in blood samples of individ�als of a rare blood gro�p 
p in considerably larger q�antities. The PF glycolipid 
is also present in h�man erythrocytes in low amo�nts 
[�����]. Whether the antibodies reactive to terminated 
saccharides can bind self antigens, i.e., linear X� and 
PF pentaglycosylceramides� needs investigation.
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A significantly higher ser�m level of anti­GalNAcβ� 
­GalNAcα and ­GlcNAcβ IgG antibodies was fo�nd in pa­
tients with anti­phospholipid syndrome vers�s normal 
controls. Besides� the elevated level of anti­GalNAcβ IgG 
is associated with fetal loss that may have a predicting im­
portance in pregnancy [��]. These data provide evidence 
abo�t the possible a�toreactivity of GalNAcβ antibodies.
Commensal microbes keep o�r imm�ne system 
healthy correcting imm�ne imbalances by different 
mechanisms [��]. Gastrointestinal t�mors germ 
and develop in the environment of commensal and 
pathogenic microbiota. The t�mor colonization 
of some genera may ca�se apoptosis in t�mors or� 
on the contrary� promote the t�mor progression 
[�����]. We s�ggest that the level of GalNAcβ an­
tibodies is indirectly associated with s�rvival. The 
antibody level and its change in patients may reflect 
the colonization by microorganisms� which benefi­
cially infl�ence s�rvival via interrelations within the 
triad microbiota — t�mor — host imm�ne response. 
Which microorganisms reg�late the systemic imm�ne 
response and increase the antibody level in patients 
with cancer remains �nknown.
We demonstrated lately the prognostic val�e of de­
termination of TF� Tn and αGal antibodies level in patients 
with gastrointestinal cancer. The combined determina­
tion of TF and αGal antibody level was more informative 
and co�ld predict s�rvival more acc�rately than the 
determination of each level separately �the man�script 
is presented for p�blication�. Significant differences 
in s�rvival� HR and mean s�rvival time val�es calc�lated 
in the present st�dy exhibit a prognostic meaning of the 
determination of GalNAcβ antibodies level. This st�dy 
provides additional information to improve the prognostic 
potential of the combined determination of two or more 
antibody markers and select patho­morphological 
gro�ps for clinical o�tcome assessment.
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